drugset
drugset / Trial / NCT01222403

A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

NCT01222403 ↗

Phase 4 Completed 767 enrolled Novartis Vaccines
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study will evaluate the safety of an influenza (flu) vaccine in Korean men and women aged 65 years and older.

Timeline

Start
2010-10
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluad Vaccine — —
Subject Vantaflu Unknown — —

Indications

influenza